CPT® Code 86654

Official Description

Antibody; encephalitis, Western equine

Common Language Description

The CPT® Code 86654 refers to a laboratory test specifically designed to measure antibodies associated with Western equine encephalitis (WEE) in serum and/or cerebrospinal fluid (CSF). Western equine encephalitis is a viral infection that is prevalent across the United States and Canada, with a higher incidence of outbreaks reported in the Western states and provinces. The clinical presentation of WEE typically begins with a sudden onset of headache and fever, which may be accompanied by symptoms such as photophobia, malaise, abdominal pain, nausea, vomiting, sore throat, and respiratory issues. As the condition progresses, the headache may worsen over several days, potentially leading to drowsiness, restlessness, and in severe cases, coma. Infants and children are particularly vulnerable to the central nervous system complications associated with this infection, and the recovery process can be prolonged, lasting from months to years. The laboratory test detects specific antibodies in the patient's blood or CSF. IgG antibody titers can indicate either a current or past infection with WEE, while the presence of IgM antibodies suggests a current or recent infection. It is important to note that both IgG and IgM antibodies may exhibit cross-reactivity with antibodies from Eastern equine encephalitis (EEE) infection, which can complicate the interpretation of results. When evaluating symptomatic patients, healthcare providers should consider the patient's travel history, along with relevant medical and epidemiological data, especially if the virus has not been isolated. The collection of a blood sample for serum testing is performed through a separately reportable venipuncture, while CSF is obtained via a separately reportable lumbar puncture. The testing of serum and CSF samples is conducted using semi-quantitative indirect fluorescent antibody or immunofluorescent assay techniques.

1. Indications

The laboratory test associated with CPT® Code 86654 is indicated for the evaluation of patients who exhibit symptoms consistent with Western equine encephalitis (WEE). The following conditions and symptoms warrant the performance of this test:

Headache and Fever: Sudden onset of headache and fever are primary symptoms that may indicate a WEE infection.
Photophobia: Sensitivity to light, which can accompany the headache and fever.
Malaise: A general feeling of discomfort or uneasiness that may be present in affected individuals.
Gastrointestinal Symptoms: Abdominal pain, nausea, and vomiting may occur as part of the clinical presentation.
Respiratory Problems: Symptoms affecting the respiratory system may also be observed.
Neurological Symptoms: Drowsiness, restlessness, and in severe cases, coma, particularly in infants and children who are more susceptible to central nervous system disease.

2. Procedure

The procedure for testing antibodies for Western equine encephalitis involves several key steps, which are outlined below:

Step 1: Patient Evaluation - The healthcare provider evaluates the patient for symptoms indicative of WEE, including headache, fever, and other neurological signs. A thorough medical history and travel history are taken into account to assess potential exposure to the virus.
Step 2: Sample Collection - A blood sample is obtained through a separately reportable venipuncture to collect serum for testing. Additionally, cerebrospinal fluid (CSF) is collected via a separately reportable lumbar puncture if indicated by the patient's condition.
Step 3: Laboratory Testing - The collected serum and CSF samples are subjected to testing using semi-quantitative indirect fluorescent antibody or immunofluorescent assay techniques. These methods are employed to detect the presence of IgG and IgM antibodies specific to WEE.
Step 4: Result Interpretation - The laboratory results are interpreted by healthcare professionals, taking into consideration the presence of IgG and IgM antibodies, as well as the potential for cross-reactivity with Eastern equine encephalitis (EEE) antibodies.

3. Post-Procedure

After the procedure, patients may experience some discomfort at the venipuncture or lumbar puncture sites. It is important for healthcare providers to monitor patients for any adverse reactions following the collection of CSF. The results of the antibody testing will guide further clinical management and treatment decisions. Patients should be informed about the potential duration for receiving test results and any follow-up appointments that may be necessary to discuss the findings and implications for their health.

Short Descr	ENCEPHALTIS WEST EQNE ANTBDY
Medium Descr	ANTIBODY ENCEPHALITIS WESTRN EQUINE
Long Descr	Antibody; encephalitis, Western equine
Status Code	Statutory Exclusion (from MPFS, may be paid under other methodologies)
Global Days	XXX - Global Concept Does Not Apply
PC/TC Indicator (26, TC)	9 - Not Applicable
Multiple Procedures (51)	9 - Concept does not apply.
Bilateral Surgery (50)	9 - Concept does not apply.
Physician Supervisions	09 - Concept does not apply.
Assistant Surgeon (80, 82)	9 - Concept does not apply.
Co-Surgeons (62)	9 - Concept does not apply.
Team Surgery (66)	9 - Concept does not apply.
Diagnostic Imaging Family	99 - Concept Does Not Apply
CLIA Waived (QW)	No
APC Status Indicator	Conditionally packaged laboratory tests
Type of Service (TOS)	5 - Diagnostic Laboratory
Berenson-Eggers TOS (BETOS)	T1H - Lab tests - other (non-Medicare fee schedule)
MUE	2
CCS Clinical Classification	235 - Other Laboratory

Reference (outside) laboratory: when laboratory procedures are performed by a party other than the treating or reporting physician or other qualified health care professional, the procedure may be identified by adding modifier 90 to the usual procedure number.

Repeat clinical diagnostic laboratory test: in the course of treatment of the patient, it may be necessary to repeat the same laboratory test on the same day to obtain subsequent (multiple) test results. under these circumstances, the laboratory test performed can be identified by its usual procedure number and the addition of modifier 91. note: this modifier may not be used when tests are rerun to confirm initial results; due to testing problems with specimens or equipment; or for any other reason when a normal, one-time, reportable result is all that is required. this modifier may not be used when other code(s) describe a series of test results (eg, glucose tolerance tests, evocative/suppression testing). this modifier may only be used for laboratory test(s) performed more than once on the same day on the same patient.